Phase I, Open Label Study to Evaluate Safety, Tolerability and Immunogenicity of Multiple Combinations of H1 and H5 Influenza Hemagglutinin Plasmids Administered ID Followed by in Vivo Electroporation With CELLECTRA-3P in Healthy Adults.

Trial Profile

Phase I, Open Label Study to Evaluate Safety, Tolerability and Immunogenicity of Multiple Combinations of H1 and H5 Influenza Hemagglutinin Plasmids Administered ID Followed by in Vivo Electroporation With CELLECTRA-3P in Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2014

At a glance

  • Drugs INO 3510 (Primary) ; Influenza virus DNA vaccine; Influenza virus vaccine
  • Indications Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype
  • Focus Adverse reactions
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 28 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Apr 2013 Data for H1N1 were presented at the World Vaccine Congress, according to an Inovio Pharmaceuticals media release.
    • 16 Mar 2012 Interim results are expected to be available in the second quarter of 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top